Korea Research Institute of Bioscience and Biotechnology

St Pharm Co., Ltd.

Hee Gu Lee

Young Il Yeom

Eun Young Song

Young Ho Kim

Jae Wha Kim

Kyung-Sook Chung

Moon Hee Kim

Kyeong-Eun Jung

Misun Won

Kyung Bin Song

Chae Ok Yun

Young Joo Kim

Yu-Kyoung Oh

Mi Sun Won

Seon-Young Kim

Jong Tae Kim

Hye Kyung Hong

Ho Kyung Chun

Min Ah Kang

Kyung Seop Ahn

Sei Ryang Oh

Ok-Kyoung Kwon

Chae-Ok Yun

Young-Jun Kim

Ho Bum Kang

Kyung Sook Chung

Kyung Ho Lee

Bo Yeon Kim

Jong Seog Ahn

Seung Ho Kim

Young-Joo Kim

Kyung Chan Park

Hyang Sook Yoo

Jae-Hyuk Jang

Hyuk Hwan Song

Dur Han Kwon

Nak Kyun Soung

Joonsung Hwang

Jae Hun Cheong

Hyunjoo Cha

Mi Young Cho

Yong-Kyung Choe

Mi-Young Park

Mija Ahn

In Ja Ryoo

Do Young Yoon

Da Jung Ji

Jeong Hae Choi

Seon Young Kim

Chang Mo Kang

Hyang Sin Lee

Jong Seok Lim

Seung Chul Choi

Jin Sook Kim

Sung-Kyun Ko

Srinivasrao Ganipisetti

Jiyun Mun

Kyoung Eun Baek

In Seong Choe

Mi Young Park

Sun-Jung Cho

Shin-Jung Choi

Ji Won Ahn

Khiev Piseth

Byeong Hwa Jeon

Jang Mi Son

The present invention relates to a composition for preventing, alleviating or treating inflammatory diseases, comprising, as an active ingredient, an acylhydrazone derivative compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. an acylhydrazone derivative compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of the present invention, effectively inhibits inflammatory cytokines and inflammatory signaling pathways, thereby effectively alleviating symptoms of inflammatory diseases such as dermatitis. Therefore, the composition according to the present invention may be effectively used for the prevention, alleviation or treatment of inflammatory diseases.

Anti-inflammatory composition comprising acylhydrazone derivative

The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.

Pharmaceutical composition for treating cancer

The present invention relates to a biomarker for gastric cancer, CST1 (cysteine proteinase inhibitor, type 2 family), DCC1 (Defective in sister chromatid cohesion homolog 1), IFITM1 (interferon induced transmembrane protein 1) or MELK (maternal embryonic leucine zipper kinase). More particularly, the present invention relates to a diagnostic composition for gastric cancer comprising an agent measuring the expression level of CST1, DCC1, IFITM1 or MELK, a kit comprising the composition, a method for detecting the marker, and a method for screening a therapeutic agent for gastric cancer using the marker.

CST1, DCC1, IFITM1 or MELK as markers for diagnosing stomach cancer

The present invention relates to a pharmaceutical composition for treating wounds or revitalizing skin comprising theextract, the fractions thereof, or the diterpene compound isolated therefrom as an active ingredient. Theextract may act on epithelial cells to induce PKD1 activity required for improving the reproduction capability of differentiated epithelial cells, and thus may induce the phosphorylation of lower ERK1 and the generation of Cycline D, thus exhibiting an excellent ability to activate the reproduction of damaged skin. Therefore, theextract may be used effectively as an active ingredient in a pharmaceutical composition for treating wounds or reproducing skin, a health food for recovering skin damage or reproducing skin, or a functional cosmetic for inducing skin cell activity.

[object Object]

Disclosed are novel GPCR (G Protein Coupled Receptor) proteins and genes encoding the same. Also provided is the use of the proteins and the genes. Particularly, contemplated are a novel GPCR (G Protein Coupled Receptor) polypeptide, a polynucleotide coding for the same, a recombinant vector carrying the polynucleotide or a fragment thereof, host cells transformed with the vector, a transgenic animal infected with the vector. Also, a composition for detecting a cancer marker, comprising an agent capable of measuring the expression level of mRNA or protein of the GPCR polynucleotide, a kit for the diagnosis of cancer, comprising the composition, and a method for detecting the GPCR polypeptide and a gene encoding the polypeptide are provided. Further, a composition for the treatment and prevention of cancer, comprising an oligonucleotide inhibiting the expression of a gene encoding the GPCR polypeptide or an antibody against the GPCR protein, and a method for screening a modulator of the GPCR protein or a cancer therapeutic agent are provided.

G protein coupled receptor protein and use thereof

Provided are a composition for diagnosing cancer or screening an anticancer drug comprising an FLJ25416 gene or an antibody directed to a protein expressed from the FLJ25416 gene, a composition for treating cancer comprising an inhibitor of the gene or an inhibitor of the protein expressed from the gene and a pharmaceutically acceptable carrier, and a kit for diagnosing cancer comprising at least one of the FLJ25416 gene and the protein expressed from the FLJ25416 gene. The FLJ25416 gene is expressed at high level in specific cancer cells, and induces an increase in proliferation rate of normal cells. The expression of the gene is suppressed, which results in an inhibitory effect on cancer cell growth. Thus, the FLJ25416 gene can be used as a target gene for diagnosis or treatment of cancer.

Use of FLJ25416 gene

Disclosed herein is a colorectal cancer marker for diagnosing colorectal cancer based on ESM-I overexpression in tissues, cells or body fluids of colorectal cancer patients. Disclosed also is the use of the colorectal cancer marker in the development of therapeutic agents for cancer and in the diagnosis and treatment of colorectal cancer.

Characterization of ESM-1 as a tumor associated marker of colorectal cancer

The present invention relates to a monoclonal antibody specific for N-myc downstream regulated gene 2 (NDRG 2) protein, a cell line producing the monoclonal antibody, a method for measuring a quantity and quality of NDRG 2 protein, and a protein chip using the same. In the present invention, NDRG 2, a cancer-related factor is specifically expressed in dendritic cells differentiated from a monocyte of human peripheral blood. Accordingly, the monoclonal antibody specific for the NDRG 2 protein, the protein chip comprising the same and the method for measuring a quantity and quality of the NDRG 2 protein by using the same can be applied to elucidate characteristics of the dendritic cell and perform a research on the NDRG 2. Therefore, the present invention may help clinically to investigate and treat intractable diseases and cancers using the dendritic cell.

Growing community of inventors

Daejeon, South Korea

Hee Gu Lee